Astrazeneca Ab

Xiaolan Zheng

Jeffrey Wallace Johannes

Michelle Lamb

Alexander Hird

Qing Ye

Daniel T Robbins

Dedong Wu

Bo Peng

Wenzhan Yang

Steven Kazmirski

Sebastien Louis Degorce

Sudhir Mahadeo Hande

Avipsa Ghosh

Paul Secrist

Matthew Belmonte

Leslie Dakin

Sandra Ann Filla

Michael Howard Block

Martin John Packer

Maria-Elena Theoclitou

Craig Robert Stewart

John Paul Secrist

Claude Afona Ogoe

Audrey Davies

Brian Aquila

Thomas Gero

Timothy Pontz

Cati Ferrar

Jayachandran Ezhuthachan

Daniel John Russell

Martin Packer

Simon Hardy

Jan Koek

Debasis Hazra

Andrew Stark

James Edward Dowling

Jon Read

David Scott

Matthew Alan Belmonte

Daniel William Robbins

Steven Lee Kazmirski

Michelle Laurae Lamb

Jeffrey Johannes

Donald Cook

David Del Valle

The present invention relates to azaquinolone compounds of Formula (I), and their use in medicine.

Chemical compounds

Disclosed is a compound which is 17-chloro-5,13,14,22-tetramethyl-28-oxa-2,9-dithia-5,6,12,13,22-pentaazaheptacyclo[27.7.1.10000]octatriaconta-1(37),4(38),6,11,14,16,18,20,23,29,31,33,35-tridecaene-23-carboxylic acid (Formula I) and enantiomers and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions of 17-chloro-5,13,14,22-tetramethyl-28-oxa-2,9-dithia-5,6,12,13,22-pentaazaheptacyclo[27.7.1.10000]octatriaconta-1(37),4(38),6,11,14,16,18,20,23,29,31,33,35-tridecaene-23-carboxylic acid, and enantiomers and pharmaceutically acceptable salts thereof, and methods of treating cancer with such compounds and compositions.

Mcl-1 inhibitors and methods of use thereof

Disclosed are intermediates and methods of synthesizing Compound 1. 

Synthesis of Mcl-1 inhibitor

Disclosed is a compound which is 17-chloro-5,13,14,22-tetramethyl-28-oxa-2,9-dithia-5,6,12,13,22-pentaazaheptacyclo[27.7.1.10,000]octatriaconta-1(37),4(38),6,11,14,16,18,20,23,29,31,33,35-tridecaene-23-carboxylic acid (Formula I) and enantiomers and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions of 17-chloro-5,13,14,22-tetramethyl-28-oxa-2,9-dithia-5,6,12,13,22-pentaazaheptacyclo[27.7.1.10000]octatriaconta-1(37),4(38),6,11,14,16,18,20,23,29,31,33,35-tridecaene-23-carboxylic acid, and enantiomers and pharmaceutically acceptable salts thereof, and methods of treating cancer with such compounds and compositions.

MCL-1 inhibitors and methods of use thereof

The invention relates to chemical compounds of formula (I), and salts thereof. In some embodiments, the invention relates to inhibitors or modulators of PIM-1 and/or PIM-2, and/or PIM-3 protein kinase activity or enzyme function. In still further embodiments, the invention relates to pharmaceutical compositions comprising compounds disclosed herein, and their use in the prevention and treatment of PIM kinase related conditions and diseases, preferably cancer. 

Chemical compounds 251

The invention relates to chemical compounds of formula (I): or pharmaceutically acceptable salts thereof which possess CSF-1R kinase inhibitory activity and are accordingly useful for their anti-cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments of use in the production of an anti-cancer effect in a warm-blooded animal such as man.

3-cinnolinecarboxamide derivatives and their use for treating cancer

This invention relates to novel compounds having the structural formula (I) and to their pharmaceutical compositions and to their methods of use. These novel compounds provide a treatment or prophylaxis of cancer.

Enantiomers of selected fused heterocyclics and uses thereof

Growing community of inventors

Waltham, MA, United States of America

Xiaolan Zheng